Merck & Co., Inc. (NYSE:MRK - Get Free Report) shot up 0.3% on Friday . The company traded as high as $101.61 and last traded at $101.51. 1,660,476 shares traded hands during trading, a decline of 82% from the average session volume of 9,249,676 shares. The stock had previously closed at $101.25.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on MRK. UBS Group cut their target price on Merck & Co., Inc. from $142.00 to $136.00 and set a "buy" rating for the company in a research note on Wednesday, October 9th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $155.00 target price on shares of Merck & Co., Inc. in a research note on Thursday, October 3rd. Wells Fargo & Company dropped their price target on shares of Merck & Co., Inc. from $125.00 to $110.00 and set an "equal weight" rating for the company in a research note on Friday, November 1st. BMO Capital Markets cut their price objective on Merck & Co., Inc. from $150.00 to $136.00 and set an "outperform" rating for the company in a research report on Friday, November 1st. Finally, Daiwa Capital Markets lowered Merck & Co., Inc. from a "buy" rating to a "neutral" rating in a research report on Monday, November 11th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $129.20.
View Our Latest Report on MRK
Merck & Co., Inc. Trading Up 1.3 %
The firm has a market cap of $259.44 billion, a price-to-earnings ratio of 21.28, a PEG ratio of 1.43 and a beta of 0.39. The business has a fifty day moving average of $103.41 and a two-hundred day moving average of $115.15. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.57 earnings per share for the quarter, beating analysts' consensus estimates of $1.50 by $0.07. Merck & Co., Inc. had a return on equity of 36.42% and a net margin of 19.23%. The business had revenue of $16.66 billion during the quarter, compared to analysts' expectations of $16.47 billion. During the same quarter last year, the business posted $2.13 earnings per share. The business's revenue for the quarter was up 4.4% on a year-over-year basis. As a group, equities analysts expect that Merck & Co., Inc. will post 7.73 earnings per share for the current fiscal year.
Merck & Co., Inc. Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 8th. Shareholders of record on Monday, December 16th will be issued a $0.81 dividend. The ex-dividend date of this dividend is Monday, December 16th. This is an increase from Merck & Co., Inc.'s previous quarterly dividend of $0.77. This represents a $3.24 annualized dividend and a yield of 3.16%. Merck & Co., Inc.'s payout ratio is 64.57%.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Darwin Wealth Management LLC purchased a new stake in Merck & Co., Inc. during the third quarter valued at about $32,000. AM Squared Ltd acquired a new stake in Merck & Co., Inc. in the third quarter valued at approximately $34,000. Safe Harbor Fiduciary LLC purchased a new position in Merck & Co., Inc. in the 3rd quarter valued at about $34,000. Peterson Financial Group Inc. acquired a new position in shares of Merck & Co., Inc. in the third quarter worth about $36,000. Finally, Itau Unibanco Holding S.A. purchased a new position in Merck & Co., Inc. in the second quarter valued at about $39,000. Institutional investors and hedge funds own 76.07% of the company's stock.
About Merck & Co., Inc.
(
Get Free Report)
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Merck & Co., Inc., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.
While Merck & Co., Inc. currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
